DiaCarta Receives CE/IVD for its New COVID 19 Test that Identifies Delta Plus and New Variants
Pleasanton, California, August 12, 2021.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore, can now be commercialized within the EU and rest of the world. This new test screens for the SARS-CoV-2 virus and simultaneously identifies and differentiates all the new mutating COVID 19 variants including the Alpha (UK), Beta (S. Africa), Gamma (Brazil), Delta (India), Delta Plus (India), Epsilon (California) and the Kappa (India) variants.
This new multiplex qPCR-based test can be run on commonly available qPCR cyclers, thereby, bypassing the need to perform expensive and time-consuming Next-generation sequencing (NGS). The test demonstrates enhanced sensitivity and specificity and is powered by DiaCarta’s proprietary XNA based Molecular Clamping Technology. This technology uses innovative synthetic Xenonucleic acid molecular oligomers (XNA) that hybridize with target DNA sequences and can be employed as molecular clamps in quantitative real-time polymerase chain reactions (qPCR). The XNA tightly bound to the wild-type sequences specifically enables only the mutant sequences to be accurately amplified.
“Expensive and time-consuming NGS assays are currently the only option to detect new and emerging COVID-19 variants which are causing widespread global alarm, and creating an urgent need for cost-effective testing platforms that can quickly and accurately detect variants,” said Aiguo (Adam) Zhang, Ph.D., Founder and CEO of DiaCarta Inc. “Our new test shows that our XNA technology can do both – precisely detect known and emerging SARS-CoV-2 mutations and provide an expeditious, inexpensive solution for variant surveillance. We are grateful for receiving the CE/IVD mark for this test as it will allow us to bring this test to the large European population to help them in their immuno-surveillance efforts.”
DiaCarta is also pursuing an Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for this unique and rapid SARS-CoV-2 variant detection test.
About DiaCarta Inc.
DiaCarta is a molecular diagnostics company that has developed innovative technologies that transform patient care by providing effective precision diagnostics using liquid biopsy. In addition to its FDA EUA approved QuantiVirus™ SARS-CoV-2 Tests, DiaCarta offers a range of testing services, from single-gene QClamp® qPCR tests to its OptiSeq™ XNA-NGS panels. The company is well positioned as a leader in the new ‘liquid biopsy’ In Vitro Diagnostics field with high-precision detection of ctDNA. Its novel XNA technology provides high level of sensitivity as it clamps the wild-type sequence and amplifies the mutant target sequence. Using this technology, the company has developed its highly sensitive, early detection ColoScape™ Colorectal Cancer test using blood. Powered by its SuperbDNA™ technology that provides high level of detection by amplifying the signal and requiring no RNA/DNA extraction or amplification, the company has developed its revolutionary RadTox™ test that personalizes radiation therapy, mitigates adverse events, and enhances patient care. Based in Pleasanton, California the company is ISO certified, GMP-compliant and offers CLIA certified laboratory services to its customers. www.diacarta.com
Contacts:
Corporate
Ram Vairavan, Ph.D.
SVP of BD
rvairavan@diacarta.com
760-402-6335
Media
Olipriya Das, Ph.D.
Russo Partners
olipriya.das@russopartnersllc.com
646-942-5588
SOURCE DiaCarta Inc.
DiaCarta Helps Communities Scale Up Their MPOX Testing Efforts with Its Simple, Reliable, and FDA-EUA-Approved MPOX Testing Kits
DiaCarta, Inc., an experienced in-vitro diagnostics (IVD) company that provided COVID-19 testing kits during the global pandemic, has expanded its focus to mpox detection and the detection of other infectious diseases.
DiaCarta and Capstone Health Alliance Collaborate to Bring Revolutionary Diagnostic Tests to Enhance Patient Care
DiaCarta, Inc., a pioneer in developing innovative molecular technologies to transform patient care by providing effective precision diagnostics using liquid biopsy in cancer and infectious diseases has established a strategic collaboration with Capstone Health Alliance, one of the largest regional group purchasing organizations (GPO) in the US healthcare sector. This new collaboration brings together powerful technologies to enhance patient care.
Florida Selects DiaCarta’s cfDNA Test (RadTox™) for Statewide Use to Detect Early Response of Cancer Treatment
DiaCarta, a leading molecular diagnostics company specializing in personalized patient care through liquid biopsy, proudly announced that Florida Health Department selected “using plasma DNA concentration (DiaCarta’s RadTox™ test) for early detection of treatment response and resistance” through the Casey DeSantis Florida Cancer Innovation Fund. This fund supports deployment of the RadTox™ test throughout the State of Florida to be performed between Radiotherapy or Chemotherapy doses for real time detection of treatment response or resistance. The results will be as a real time predictor of imaging data.
DiaCarta Announces That the Oncuria® Bladder Cancer Tests Receive Medicare Coverage Effective January 1, 2024
DiaCarta proudly announced that the Oncuria® Bladder Cancer Tests, developed by Nonagen Bioscience and validated by DiaCarta as a Lab Developed Test (LDT), at its CAP-accredited and CLIA-certified laboratory, have received Medicare coverage effective January 1, 2024.
DiaCarta, Inc. and OncoAssure Ltd. Collaborate to Launch Prostate Cancer Lab Developed Test
DiaCarta, Inc. (“DiaCarta”), a pioneer in molecular diagnostic test development for cancer and infectious diseases, today announced that it has established a strategic collaboration with OncoAssure Ltd, an Irish medical diagnostics company. The focus of the collaboration is to commercialize OncoAssure’s groundbreaking Prostate test which is designed to identify patients with a lower risk of prostate cancer recurrence, guiding decisions on active surveillance or reduced monitoring post-treatment.